Rosetta Genomics Inks MDx Development Deal with Moffitt Cancer Center | GenomeWeb

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it will collaborate with the Moffitt Cancer Center on the development of a microRNA-based diagnostic for thyroid neoplasia.

According to Rosetta, between four and seven percent of the general population develops thyroid nodules, but fewer than 10 percent of these are malignant. Fine needle aspiration (FNA) is routinely conducted to obtain tissue for biopsy, but analyses of these samples are often inconclusive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.